platelet-rich plasma

Biologicalexperimental

Human platelet lysate is a substitute supplement for fetal bovine serum (FBS) in experimental and clinical cell culture. It is a turbid, light-yellow liquid that is obtained from human blood platelets after freeze/thaw cycle(s). The freeze/thaw cycle causes the platelets to lyse, releasing a large quantity of growth factors necessary for cell expansion. hPL has the highest concentration of growth factors of any serum supplements. FBS-free cell culture media, e.g. with platelet lysate or chemically defined/ animal component free, are used for cell therapy or regenerative medicine. They are commercially available in GMP -quality which is generally basis for regulatory approval. — Wikipedia

Clinical trial activity

506 trials · 370 clinical orgs · 0 marketing orgs

Phase 1
100
Phase 2
152
Phase 3
83
Phase 4
54

Earliest trial started Jun 1, 2005 (NCT00856934)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • PlasmaSupplementation

    Plasma supplementation

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • autologous human platelet lysate
  • autologous platelet rich plasma
  • autologous platelet-rich plasma
  • l-prp
  • plasma rich platelet
  • platelet lysate
  • platelet rich plasma
  • platelet-rich plasma
  • platelet-rich-plasma

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07020559Phase 4Apr 30, 2026Peking University
NCT07277998N/AMar 31, 2026Karachi Medical and Dental College
NCT07306871N/AJan 1, 2026Minia University
NCT07282288N/ADec 15, 2025Peking University
NCT07231471N/ADec 15, 2025University of Utah
NCT07151703Phase 3Oct 1, 2025Taipei Veteran General hospital
NCT06998433Phase 4Sep 30, 2025Baylor University
NCT07115797N/ASep 30, 2025Cairo University
NCT06903611Phase 3Sep 30, 2025Cambium Bio Limited
NCT07117955N/ASep 20, 2025University of Copenhagen
NCT07185802N/AAug 27, 2025Bangladesh Medical University
NCT07107399Phase 2/Phase 3 (Phase 3)Aug 5, 2025Cairo University
NCT07103551Phase 3Aug 1, 2025Al Azhar University
NCT07307118N/AJul 8, 2025Firat University
NCT06924853N/AJul 1, 2025Regenexx
NCT07005661Phase 2/Phase 3 (Phase 3)Jun 30, 2025Capital Medical University, Central South University, Guangzhou Medical University, Shantou University
NCT06372600N/AJun 1, 2025Chengdu Sport University
NCT06907121Phase 2/Phase 3 (Phase 3)Jun 1, 2025Integrant Pty Ltd, University of Technology, Sydney
NCT06930248N/AMay 1, 2025Sohag University
NCT06965088Phase 2Apr 28, 2025Mahidol University
Showing 20 of 506 trials
Page 1 / 26

Organizations

Research & Development (370)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Assiut UniversityAcademic/Hospital161652017
Cairo UniversityAcademic/Hospital131252016
Ain Shams UniversityAcademic/Hospital121152016
Government of TaiwanGovernment10722014
Mansoura UniversityAcademic/Hospital101032017
Mayo ClinicAcademic/Hospital8832016
Kaohsiung Medical UniversityAcademic/Hospital7742017
Bharat Biotech International LimitedFor profit6612012
Government of SpainGovernment6522013
University of AthensAcademic/Hospital6612019
University of MiamiAcademic/Hospital6522012
Benha UniversityAcademic/Hospital5542018
Istanbul UniversityAcademic/Hospital5522020
Sohag UniversityAcademic/Hospital5432021
Tanta UniversityAcademic/Hospital5432018
Universidad Autonoma de Nuevo LeonAcademic/Hospital5522013
University of BolognaAcademic/Hospital5522013
Zagazig UniversityAcademic/Hospital5522018
Acibadem UniversityAcademic/Hospital4422014
Aeon Astron Europe B.V.For profit4012016
370 organizations
Page 1 / 19